Clene Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CLNN Nasdaq 8731 https://clene.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Clene Inc.

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23 - Jan 11th, 2023 1:00 pm
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg - Dec 27th, 2022 9:01 pm
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland - Dec 12th, 2022 1:00 pm
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies - Nov 28th, 2022 1:00 pm
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights - Nov 7th, 2022 1:00 pm
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland - Oct 31st, 2022 12:00 pm
Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial - Oct 3rd, 2022 12:00 pm
Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3 - Sep 30th, 2022 8:12 pm
Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference - Sep 21st, 2022 11:00 am
Clene to Present at Upcoming September Investor Conferences - Aug 30th, 2022 11:00 am
Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis - Aug 15th, 2022 11:00 am
Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights - Aug 15th, 2022 11:00 am
Clene to Host VISIONARY-MS Results Call and Webcast on August 15 - Aug 12th, 2022 8:01 pm
Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS - Jul 19th, 2022 11:00 am
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial - Jul 14th, 2022 11:00 am
Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28 - Jun 27th, 2022 11:00 am
Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day - Jun 2nd, 2022 11:00 am
New Data from Clene’s RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting - Jun 1st, 2022 11:00 am
Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility - May 19th, 2022 11:30 am
Clene to Present at Upcoming Investor Conferences - May 16th, 2022 12:00 pm